The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
N-Acetyl-Semax Adamantane · Adamantyl Semax
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
Use the route notes below to match form, goal, and evidence quality.
No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
Adamax is a structurally elegant idea built on a solid foundation — and extended one step beyond what the evidence currently supports. The foundation is real. The extension has not been validated.
The central tension resolved: Semax works. The BDNF evidence is real, the Russian clinical approval is real, and the 2006 Dolotov paper at the Journal of Neurochemistry is the independent Western confirmation that gives Semax real credibility. N-Acetyl-Semax improves on Semax's stability and BBB penetration through a well-characterized N-terminal modification. The adamantane group from P21 adds C-terminal protection and dramatically increased lipophilicity. Combining all three — N-acetyl modification + adamantane C-terminus on the Semax base sequence — is a rational peptide design decision with a clear mechanistic logic. The result, Adamax, should theoretically be more potent and longer-lasting than either Semax or N-Acetyl-Semax. The problem: 'should theoretically be' is not 'has been shown to be.' No published study confirms any aspect of Adamax's specific pharmacological profile. The community is using a rationally designed compound whose expected effects are entirely borrowed from its parent compounds' published data. That is the complete picture.
Adamax's strongest argument: the structural modifications are rational, the parent compounds' evidence is solid, and the community experience is consistent with the predicted pharmacological profile (Semax-like cognitive effects, extended duration). For someone who has already used Semax and N-Acetyl-Semax and wants to explore the next structural iteration of this class, Adamax is a defensible choice — provided they understand the evidence status. Adamax's weakest link: the jump from 'Semax works' to 'this specific structural modification of Semax works better' requires data that does not exist. The 'more potent' claim has no direct evidence.
Compared to other compounds in this reference: Adamax's evidence situation is more transparent than it might appear from vendor marketing, and more concerning than community discussions typically acknowledge. Epitalon has 40 years of research from one lab — still concentrated, but 40 years. Selank has Russian pharmaceutical approval and some independent Russian-institution replication. Semax has Dolotov 2006. Adamax has none of these. It has the weakest evidence base of any compound in this reference — weaker even than the Russian neuropeptides covered in the Selank and Semax chapters, because at least those compounds have institutional clinical histories. Adamax is a novel designer peptide sold on inference.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
The Maximally-Modified Form of Semax, Built by the Community Rather Than a Pharmaceutical Company. What N-Acetylation Actually Does to a Peptide at the Molecular Level. What C-Terminal Amidation Actually Does. Why These Two Modifications Together Are Different from Either Alone. The Evidence Problem: Everything Below Is Extrapolated from Semax. NOT the Same as NA Selank Amidate (Adamax). Limitless Spray Format. Why Morning Dosing Is Not Optional.
The 7-Amino-Acid Antidepressant That Works in 4 Days Instead of 4 Weeks. TREK-1: The Potassium Channel That Keeps You Depressed. IC50 of 0.12 nM — 333x More Potent Than Its Parent Spadin. Duration Extended to 23 Hours vs 7 Hours. Hippocampal Neurogenesis in 4 Days. The Same One French Research Group Since 2010. Zero Human Trials. A Novel Mechanism That Bypasses the Serotonin Transporter Entirely.
Synthetic β-carboline heterocyclic amine with a compelling in vitro dopaminergic neuroprotective profile and zero human clinical trials. Also a MAO-A inhibitor (IC50 = 1 μM) with tyramine-reaction and serotonin-syndrome risk, plus photosensitizer concerns from UV-activated DNA damage potential.